Search research articles
Contact Us
Filters
Showing results (111-120 of 125) with videos related to
Page
of 13
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging
|
October 25, 2022
Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study
Jules Gregory, Lambros Tselikas, Caroline Allimant, et al.
Gastroenterology
|
July 4, 2012
Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria
Christophe Duvoux, Françoise Roudot-Thoraval, Thomas Decaens, et al.
Nature
|
April 22, 2026
Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer
Gael Roth, Pascal Artru, Olivier Bouche, et al.
Hepatology Communications
|
February 8, 2022
miR-579-3p Controls Hepatocellular Carcinoma Formation by Regulating the Phosphoinositide 3-Kinase-Protein Kinase B Pathway in Chronically Inflamed Liver
Cristina Quintavalle, Nathalie Meyer-Schaller, Stephanie Roessler, et al.
Lancet (London, England)
|
May 11, 2025
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
Thomas Yau, Peter R Galle, Thomas Decaens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 28, 2013
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study
Philip J Johnson, Shukui Qin, Joong-Won Park, et al.
European Journal of Gastroenterology & Hepatology
|
August 13, 2025
Real-life data on hepatocellular carcinoma in the French prospective CHIEF cohort in the era of immunotherapy
Eric Nguyen-Khac, Philippe Merle, Hajer Ben Khadhra, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
September 4, 2025
Real-World Outcomes of Atezolizumab-Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort
Manon Allaire, Elhadji Malick Thiam, Guiliana Amaddeo, et al.
Clinics and Research in Hepatology and Gastroenterology
|
April 30, 2021
Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study
Laurent Lam, Hélène Fontaine, Marc Bourliere, et al.
BMC Infectious Diseases
|
January 28, 2022
Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis
Georges-Philippe Pageaux, Clovis Lusivika Nzinga, Nathalie Ganne, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 125) with videos related to
Sort By:
Page
of 13
European Journal of Nuclear Medicine and Molecular Imaging
|
October 25, 2022
Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study
Jules Gregory, Lambros Tselikas, Caroline Allimant, et al.
Gastroenterology
|
July 4, 2012
Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria
Christophe Duvoux, Françoise Roudot-Thoraval, Thomas Decaens, et al.
Nature
|
April 22, 2026
Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer
Gael Roth, Pascal Artru, Olivier Bouche, et al.
Hepatology Communications
|
February 8, 2022
miR-579-3p Controls Hepatocellular Carcinoma Formation by Regulating the Phosphoinositide 3-Kinase-Protein Kinase B Pathway in Chronically Inflamed Liver
Cristina Quintavalle, Nathalie Meyer-Schaller, Stephanie Roessler, et al.
Lancet (London, England)
|
May 11, 2025
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
Thomas Yau, Peter R Galle, Thomas Decaens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 28, 2013
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study
Philip J Johnson, Shukui Qin, Joong-Won Park, et al.
European Journal of Gastroenterology & Hepatology
|
August 13, 2025
Real-life data on hepatocellular carcinoma in the French prospective CHIEF cohort in the era of immunotherapy
Eric Nguyen-Khac, Philippe Merle, Hajer Ben Khadhra, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
September 4, 2025
Real-World Outcomes of Atezolizumab-Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort
Manon Allaire, Elhadji Malick Thiam, Guiliana Amaddeo, et al.
Clinics and Research in Hepatology and Gastroenterology
|
April 30, 2021
Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study
Laurent Lam, Hélène Fontaine, Marc Bourliere, et al.
BMC Infectious Diseases
|
January 28, 2022
Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis
Georges-Philippe Pageaux, Clovis Lusivika Nzinga, Nathalie Ganne, et al.
Page
of 13